← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #284 OF 1,000 MOST-CITED

Review of representative number of batches

FDA cited this observation 77 times across 75 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs77
BY FISCAL YEAR
FY20264
FY202514
FY202413
FY20238
FY20227
FY20212
FY20202
FY20197
FY201815
FY20175

How FDA worded it — real examples

Written procedures are not followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Excel Vision · Annonay · Drugs · 2026-01-22

Written procedures are not established and followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Dabur India Limited · Dadra And Nagar Haveli · Drugs · 2026-01-16

Written procedures are not established for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Identipak Inc · Mcallen, Texas · Drugs · 2025-12-18

Written procedures are not established and followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Chartwell Pharmaceuticals Congers, LLC · Congers, New York · Drugs · 2025-11-18

Written procedures are not established and followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Intercos America, Inc. · West Nyack, New York · Drugs · 2025-09-26

Written procedures are not established and followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Chemco Corporation · Miami Lakes, Florida · Drugs · 2025-08-22

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →